Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…Abstract Number: 2440 • 2016 ACR/ARHP Annual Meeting
First Results from the Prospective German Pregnancy Register
Background/Purpose: There is limited evidence on the safety of treatment during pregnancy and lactation. With the increasing number of new therapeutic options for inflammatory rheumatic…Abstract Number: 2600 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Background/Purpose: Disease activity is the main risk factor for developing lymphoma in patients with rheumatoid arthritis (RA). However, the impact of immunosuppressive drugs remains an…Abstract Number: 2630 • 2016 ACR/ARHP Annual Meeting
EBV Load Quantification in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis Treated By Abatacept and Tocilizumab
Background/Purpose: For twenty years, the Epstein-Barr Virus (EBV) has been suspected to contribute to Rheumatoid Arthritis (RA). Immunity against EBV is impaired in RA. RA…Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…Abstract Number: 481 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old
Background/Purpose Early introductions of biologics in early rheumatoid arthritis (RA) patients are well documented, but there are few reports of biologics use in established elderly…Abstract Number: 170 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Background/Purpose: Dermatologic side effects to use of gout treatments are concerning to patients. The goal of the study was to assess the risk of occurrence…